• Explore /
  • Poster
  • / Phase 1b/2 study of combination <sup>177</sup>Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.

Abstract Poster

Authors

Elshad Hasanov

Elshad Hasanov

The University of Texas MD Anderson Cancer Center, Houston, TX

Elshad Hasanov , Lesley Flynt , Rebecca Tidwell , Hyunsoo Hwang , Roserika Brooks , Lauren Michelle Wood , Travis Solley , Dahlia Mack , Yuko Yamamura , Colin Hayward , Aradhana M. Venkatesan , Eric Jonasch

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05239533

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS496)

DOI

10.1200/JCO.2024.42.4_suppl.TPS496

Abstract #

TPS496

Poster Bd #

M17

Abstract Disclosures

Similar Posters

First Author: Elshad Hasanov

First Author: Elshad Hasanov

First Author: Guillaume Grisay

First Author: Mitch Hayes